Biogen Operating Cycle from 2010 to 2026

BIIB Stock  USD 191.20  2.21  1.17%   
Biogen's Operating Cycle is increasing over the years with slightly volatile fluctuation. Overall, Operating Cycle is expected to go to 373.39 this year. From 2010 to 2026 Biogen Operating Cycle quarterly data regression line had arithmetic mean of  307.65 and r-squared of  0.25. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
342.62522842
Current Value
373.39
Quarterly Volatility
90.01905504
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Biogen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biogen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 982.2 M, Interest Expense of 258.3 M or Selling General Administrative of 2.6 B, as well as many indicators such as Price To Sales Ratio of 2.5, Dividend Yield of 0.0028 or PTB Ratio of 1.34. Biogen financial statements analysis is a perfect complement when working with Biogen Valuation or Volatility modules.
  
Build AI portfolio with Biogen Stock
Check out the analysis of Biogen Correlation against competitors.
Analyzing Biogen's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Biogen's current valuation and future prospects.

Latest Biogen's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Biogen Inc over the last few years. It is Biogen's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biogen's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Biogen Operating Cycle Regression Statistics

Arithmetic Mean307.65
Geometric Mean286.16
Coefficient Of Variation29.26
Mean Deviation57.86
Median310.63
Standard Deviation90.02
Sample Variance8,103
Range406
R-Value0.50
Mean Square Error6,510
R-Squared0.25
Significance0.04
Slope8.86
Total Sum of Squares129,655

Biogen Operating Cycle History

2026 373.39
2025 342.63
2024 459.21
2023 442.07
2022 292.03
2021 299.02
2020 279.25

About Biogen Financial Statements

Biogen stakeholders use historical fundamental indicators, such as Biogen's Operating Cycle, to determine how well the company is positioned to perform in the future. Although Biogen investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biogen's assets and liabilities are reflected in the revenues and expenses on Biogen's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biogen Inc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 342.63  373.39 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. Projected growth potential of Biogen fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biogen assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.192
Earnings Share
8.89
Revenue Per Share
67.513
Quarterly Revenue Growth
(0.07)
Return On Assets
0.0614
Biogen Inc's market price often diverges from its book value, the accounting figure shown on Biogen's balance sheet. Smart investors calculate Biogen's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Biogen's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Biogen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biogen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.